Comparative analysis of different oral approaches to treat Vibrio cholerae infection in adult mice

International Journal of Medical Microbiology

Volumn 304, Issue 3-4, 2014, Pages 422-430

  Jaiswal, Abhishek ^a   Koley, Hemanta ^a   Mitra, Soma ^a   Saha, Dhira Rani ^a   Sarkar, Banwarilal ^a  

^a NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

Author keywords

Lytic; Oral administration; Phage cocktail; Vibrio cholerae; Vibriophage

Indexed keywords

CIPROFLOXACIN; INTERLEUKIN 6; ORAL REHYDRATION SOLUTION; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT; INTERLEUKIN-6, MOUSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COUNT; BACTERIAL LOAD; BACTERIOPHAGE; CHOLERA; CONTROLLED STUDY; DRUG SAFETY; EPITHELIUM; FEMALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; ORAL REHYDRATION THERAPY; PULSED FIELD GEL ELECTROPHORESIS; TEMPERATURE SENSITIVITY; TREATMENT OUTCOME; ANIMAL; BIOLOGICAL THERAPY; COMPARATIVE STUDY; CYTOCHEMISTRY; DISEASE MODEL; DRUG EFFECTS; FLUID THERAPY; GASTROINTESTINAL TRACT; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOLOGY; PROCEDURES; SECRETION (PROCESS); VIBRIO CHOLERAE; VIROLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; BACTERIOPHAGES; BIOLOGICAL THERAPY; CHOLERA; DISEASE MODELS, ANIMAL; FEMALE; FLUID THERAPY; GASTROINTESTINAL TRACT; HISTOCYTOCHEMISTRY; INTERLEUKIN-6; MICE; TUMOR NECROSIS FACTOR-ALPHA; VIBRIO CHOLERAE;

EID: 84899654814     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2014.02.007     Document Type: Article

References (60)

1. Alemayehu D., Casey P.G., Mcauliffe O., Guinane C.M., Martin J.G., Shanahan F., Coffey A., Ross R.P., Hill C. Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio 2012, 3. e00029-12.
2. Barrow P.A., Soothill J.S. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol. 1997, 5:268-271.
3. Bhattacharya S.K., Bhattacharya M.K., Dutta P., Dutta D., De S.P., Sikdar S.N., Maitra A., Dutta A., Pal S.C. Double-blind, randomized, controlled clinical trial of norfloxacin for cholera. Antimicrob. Agents Chemother. 1990, 34:939-940.
4. Bhowmick T.S., Koley H., Das M., Saha D.R., Sarkar B.L. Pathogenic potential of vibriophages against an experimental infection with Vibrio cholerae O1 in the RITARD model. Int. J. Antimicrob. Agents 2009, 33:569-573.
5. Biswas B., Adhya S., Washart P., Paul B., Trostel A.N., Powell B., Carlton R., Merril C.R. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect. Immun. 2002, 70:204-210.
6. Brussow H. Phage therapy: the Escherichia coli experience. Microbiology 2005, 151:2133-2140.
7. Butterton J.R., Ryan E.T., Shahin R.A., Calderwood S.B. Development of a germfree mouse model of Vibrio cholerae infection. Infect. Immun. 1996, 64:4373-4377.
8. Campbell A. The future of bacteriophage biology. Nat. Rev. Genet. 2003, 4:471-477.
9. Capparelli R., Nocerino N., Iannaccone M., Ercolini D., Parlato M., Chiara M., Iannelli D. Bacteriophage therapy of Salmonella enterica: a fresh appraisal of bacteriophage therapy. J. Infect. Dis. 2010, 201:52-61.
10. Carvalho C.M., Gannon B.W., Halfhide D.E., Santos S.B., Hayes C.M., Roe J.M., Azeredo J. The in vivo efficacy of two administration routes of a phage cocktail to reduce numbers of Campylobacter coli and Campylobacter jejuni in chickens. BMC Microbiol. 2010, 10:232.
11. Chhibber S., Kaur S., Kumari S. Therapeutic potential of bacteriophage in treating Klebsiella pneumonia B5055-mediated lobar pneumonia in mice. J. Med. Microbiol. 2008, 57:1508-1513.
12. Cholera, 2012. Wkly. Epidemiol. Rec. 2013, 88:321-334.
13. Cholera bacteriophages revisited. ICMR Bull. 2002, 4:32.
14. Comeau A.M., Tétart F., Trojet S.N., Prère M.F., Krisch H.M. Phage-Antibiotic Synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS ONE 2007, 2:e799.
15. Dabrowska K., Switała-Jelen K., Opolski A., Weber-Dabrowska B., Gorski A. Bacteriophage penetration in vertebrates. J. Appl. Microbiol. 2005, 98:7-13.
16. DuPont H.L. Diarrheal disease: current concepts and future challenges: antimicrobial therapy and prophylaxis. Trans. R. Soc. Trop. Med. Hyg. 1993, 87:31-34.
17. Filippov A.A., Sergueev K.V., He Y., Huang X.Z., Gnade B.T., Mueller A.J., Fernandez-Prada C.M., Nikolich M.P. Bacteriophage therapy of experimental bubonic plague in mice. Adv. Exp. Med. Biol. 2012, 954:337-348.
18. Górski A., Miedzybrodzki R., Borysowski J., Weber-Dabrowska B., Lobocka M., Fortuna W., Letkiewicz S., Zimecki M., Filby G. Bacteriophage therapy for the treatment of infections. Curr. Opin. Investig. Drugs. 2009, 10:766-774.
19. Gottuzo E., Seas C., Echevarria J., Carrillo C., Mostorino R., Ruiz R. Ciprofloxacin for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults. Clin. Infect. Dis. 1995, 20:1485-1490.
20. Hatfull G.F. Bacteriophage genomics. Curr. Opin. Microbiol. 2008, 11:447-453.
21. Hirschhorn N., Kinzie J.L., Sachar D.B., Northrup R.S., Taylor J.O., Ahmad S.Z., Phillips R.A. Decrease in net stool output in cholera during intestinal perfusion with glucose-containing solutions. N. Engl. J. Med. 1968, 279:176-181.
22. Jaiswal A., Koley H., Ghosh A., Palit A., Sarkar B. Efficacy of cocktail phage therapy in treating Vibrio cholerae infection in rabbit model. Microbes Infect. 2013, 15:152-156.
23. Khan W.A., Begum M., Salam M.A., Bardhan P.K., Islam M.R., Mahalanabis D. Comparative trial of five antimicrobial compounds in the treatment of cholera in adults. Trans. R. Soc. Trop. Med. Hyg. 1995, 89:103-106.
24. Kirby A.E. Synergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureus. PLoS ONE 2012, 7:e51017.
25. Kochetkova V.A., Mamontov A.S., Moskovtseva R.L., Erastova E.I., Trofimov E.I., Popov M.I., Dzhubalieva S.K. Phagotherapy of postoperative suppurative-inflammatory complications in patients with neoplasms. Sov. Med. 1989, 6:23-26.
26. Kumari S., Harjai K., Chhibber S. Efficacy of bacteriophage treatment in murine burn wound infection induced by Klebsiella pneumoniae. J. Microbiol. Biotechnol. 2009, 19:622-628.
27. Lederberg J. Smaller fleas ad infinitum: therapeutic bacteriophage redux. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:3167-3168.
28. Ling Y.L., Meng A.H., Zhao X.Y., Shan B.E., Zhang J.L., Zhang X.P. Effect of cholecystokinin on cytokines during endotoxic shock in rats. World J. Gastroenterol. 2001, 7:667-671.
29. Lu Z., Breidt F., Plengvidhya V., Fleming H.P. Bacteriophage ecology in commercial sauerkraut fermentations. Appl. Environ. Microbiol. 2003, 69:3192-3202.
30. Maura D., Debarbieux L. On the interactions between virulent bacteriophages and bacteria in the gut. Bacteriophage 2012, 2:229-233.
31. Maura D., Galtier M., Le Bouguénec C., Debarbieux L. Virulent bacteriophages can target O104:H4 enteroaggregative Escherichia coli in the mouse intestine. Antimicrob. Agents Chemother. 2012, 56:6235-6242.
32. McKay D.M., Halton D.W., Johnston C.F., Fairweather I., Shaw C. Hymenolepis diminuta: changes in intestinal morphology and the enterochromaffin cell population associated with infection in male C57 mice. Parasitology 1990, 101:107-113.
33. Merril C.R., Scholl D., Adhya S.L. The prospect for bacteriophage therapy in Western medicine. Nat. Rev. Drug Discov. 2003, 2:489-497.
34. Miller R.W., Skinner E.J., Sulakvelidze A., Mathis G.F., Hofacre C.L. Bacteriophage therapy for control of necrotic enteritis of broiler chickens experimentally infected with Clostridium perfringens. Avian Dis. 2010, 54:33-40.
35. National Committee for Clinical Laboratory Standards Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Fifth Edition: Approved Standard M7-A5 2000, NCCLS, Wayne, PA, USA.
36. Nelson E.J., Nelson D.S., Salam M.A., Sack D.A. Antibiotics for both moderate and severe cholera. N. Engl. J. Med. 2011, 364:5-7.
37. O'Flynn G., Ross R.P., Fitzgerald G.F., Coffey A. Evaluation of a cocktail of three bacteriophages for biocontrol of Escherichia coli O157:H7. Appl. Environ. Microbiol. 2004, 70:3417-3424.
38. Oliveira A., Sereno R., Azeredo J. In vivo efficiency evaluation of a phage cocktail in controlling severe colibacillosis in confined conditions and experimental poultry houses. Vet. Microbiol. 2010, 146:303-308.
39. Olivier V., Queen J., Satchell K.J. Successful small intestine colonization of adult mice by Vibrio cholerae requires ketamine anesthesia and accessory toxins. PLoS ONE 2009, 4:e7352.
40. Olson M.R., Axler R.P., Hicks R.E. Effects of freezing and storage temperature on MS2 viability. J. Virol. Meth. 2004, 122:147-152.
41. Oral Rehydration Salts: Production of the New ORS 2006, WHO/FCH/CAH/06.1.
42. Phage therapy [Editorial]. Lancet 1983, 2:1287-1288.
43. Pierce N.F., Banwell J.G., Rupak D.M., Mitra R.C., Caranasos G.J., Keimowitz R.I., Mondal A., Manji P.M. Effect of intragastric glucose-electrolyte perfusion upon water and electrolyte balance in Asiatic cholera. Gastroenterology 1968, 55:43-333.
44. Pirisi A. Phage therapy: advantages over antibiotics?. Lancet 2000, 356:1418.
45. Richardson S.H. Animal models in cholera research. Vibrio Cholerae and Cholera 1994, 203-226. ASM Press, Washington, D. C. I.K. Wachsmuth, P.A. Blake, T. Olsvik (Eds.).
46. Reynaud A., Cloastre L., Bernard J., Laveran H., Ackermann H.W., Licois D., Joly B. Characteristics and diffusion in the rabbit of a phage for Escherichia coli 0103. Attempts to use this phage for therapy. Vet. Microbiol. 1992, 30:203-212.
47. Saha D.R., Pal A., Rajendran K., Dutta P. Histopathological changes in experimental cholera with a non-toxigenic non-O1 non-O139 Vibrio cholerae strain isolated from Kolkata, India. Indian J. Exp. Biol. 2006, 44:221-227.
48. Sarkar B.L., De S.P., Saha M.R., Niyogi S.K., Roy M.K. Validity of new phage typing scheme against Vibrio cholerae O1 biotype El Tor strains. Indian J. Med. Res. 1994, 99:159-161.
49. Schuch R., Nelson D., Fischetti V.A. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 2002, 418:884-889.
50. Sheng H., Knecht H.J., Kudva I.T., Hovde C.J. Application of bacteriophages to control intestinal Escherichia coli O157:H7 levels in ruminants. Appl. Environ. Microbiol. 2006, 72:5359-5366.
51. Shen G.H., Wang J.L., Wen F.S., Chang K.M., Kuo C.F., Lin C.H., Luo H.R., Hung C.H. Isolation and characterization of φkm18p, a novel lytic phage with therapeutic potential against extensively drug resistant Acinetobacter baumannii. PLoS ONE 2012, 7:e46537.
52. Smith H.W., Huggins M.B. Successful treatment of experimental Escherichia coli infections in mice using phages: its general superiority over antibiotics. J. Gen. Microbiol. 1982, 128:307-318.
53. Sulakvelidze A., Alavidze Z., Morris J.G. Bacteriophage therapy. Antimicrob. Agents Chemother. 2001, 45:649-659.
54. Summers W.C. Bacteriophage therapy. Annu. Rev. Microbiol. 2001, 55:437-451.
55. Sunagar R., Patil S.A., Chandrakanth R.K. Bacteriophage therapy for Staphylococcus aureus bacteremia in streptozotocin-induced diabetic mice. Res. Microbiol. 2010, 161:854-860.
56. Tey B.T., Ooi S.T., Yong K.C., Tan N.g.M.Y., Ling T.C., Tan W.S. Production of fusion m13 phage bearing the disulphide constrained peptide sequence (C-WSFFSNI-C) that interacts with hepatitis B core antigen. J. Afr. Biotechnol. 2009, 8:268-273.
57. Verma V., Harjai K., Chhibber S. Characterization of a T7-like lytic bacteriophage of Klebsiella pneumoniae B5055: a potential therapeutic agent. Curr. Microbiol. 2009, 59:274-281.
58. Watanabe R., Matsumoto T., Sano G., Ishii Y., Tateda K., Sumiyama Y., Uchiyama J., Sakurai S., Matsuzaki S., Imai S., Yamaguchi K. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob. Agents Chem. 2007, 51:446-452.
59. World Health Organization Cholera: can rehydration therapy be improved?. WHO Drug Inf. 2000, 14:88.
60. World Health Organization Guidelines for Cholera Control 1993, Geneva, Switzerland.